Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study

摘要: Background/Aims Treatment of hepatorenal syndrome (HRS) is based on vasoconstrictors. Terlipressin the one with soundest evidence. Noradrenalin has been suggested as an effective alternative. The current study was aimed at assessing efficacy and safety noradrenalin vs terlipressin in patients HRS. Methods Twenty-two consecutive cirrhotic HRS (9 type 1; 13 2) were included. Patients randomly assigned to be treated (0.1–0.7μg/kg/min) albumin (10 patients) or (1–2mg/4h) (12 patients). administered until reversal for a maximum two weeks. followed-up liver transplantation death. Results Reversal observed 7 10 (70%) 12 (83%) terlipressin, p =ns. led both groups significant improvement renal circulatory function. No patient developed signs myocardial ischemia. Conclusions Data from this unblinded, pilot suggest that safe These results would support use noradrenalin, cheap widely available drug, management these patients.